Biotechnological war against biofilms. Could phages mean the end of device-related infections?
Related Experiment Video
Updated: Jul 11, 2026

Anti-virulent Disruption of Pathogenic Biofilms using Engineered Quorum-quenching Lactonases
Published on: January 1, 2016
J L Del Pozo1, M Alonso, C R Arciola
1Division of Infectious Diseases and Clinical Microbiology, Clínica Universitaria de Navarra, Pamplona, Spain. jldelpozo@unav.es
Abstract:
Microorganisms universally attach to surfaces, resulting in biofilm formation. These biofilms entail a serious problem in daily clinical practice because of the great prevalence of implantable device-related infections. Differences in antibiotic activity against planktonic and sessile bacteria may relate to clinical failures in the treatment of biofilm-related infections (BRI). Bacteriophages have several characteristics that make them potentially attractive therapeutic agents in some selected clinical settings, like for example BRI. They are highly specific and very effective in lysing targeted bacteria, moreover, they appear to be safe for humans. Many studies have shown the potential of phages for the treatment of infectious diseases in plants and animals, including infections with highly drug-resistant bacteria. The therapeutic use of bacteriophages, possibly in combination with antibiotics, may be a valuable approach in BRI. However, many important questions still remain that must be addressed before phages can be endorsed for therapeutic use in humans.
Related Concept Videos
Bacterial Signaling
Biofilms
Lytic Cycle of Bacteriophages
Biological Methods for Microbial Control
Gene Regulation in Microbial Communities: Quorum Sensing
Bacteriophages of the Human Virome
